.After raising $170 million back in February, metabolic disease-focused BioAge Labs has actually filed to debut on everyone market.The Eli Lilly-partnered biotech hopes to provide on the Nasdaq under the symbolic representation "BIOA," depending on to papers submitted with the Stocks and Substitution Compensation. The provider has actually certainly not openly shared an expected monetary quantity for the offering.The clinical-stage firm promotes lead applicant azelaprag, an orally provided tiny particle slated to get in period 2 screening in combination with semaglutide-- offered through Novo Nordisk under brand Wegovy for effective weight loss-- in the 1st fifty percent of upcoming year. Semaglutide is also sold as Ozempic as well as Rybelsus by Novo for diabetic issues.
Apelin receptor agonist azelaprag is actually designed to integrate well with GLP-1 drugs, enhancing fat loss while keeping muscle mass. The investigational drug was found to be well-tolerated one of 265 people across 8 phase 1 trials, according to BioAge.Recently, BioAge got the help of Lilly to manage a test integrating azelaprag along with the Huge Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetes mellitus as Mounjaro as well as Zepbound for weight reduction. The partners are presently conducting a stage 2 trial of azelaprag as well as tirzepatide, with topline results expected in the third fourth of 2025.The biotech is also organizing a the hormone insulin sensitiveness proof-of-concept test assessing azelaprag as a monotherapy in the initial half of upcoming year to assist potential indication expansion. In addition, the firm intends to talk to the FDA for consent in the 2nd fifty percent of 2025 to release human testing for an NLRP3 inhibitor targeting metabolic conditions and also neuroinflammation.BioAge's expected transfer to the general public market follows a small uptick in planned biotech IPOs from Bicara Therapeutics and also Zenas Biopharma. Zooming out, the latest IPO yard is actually a "mixed photo," along with high-grade companies still debuting on the public markets, simply in lessened numbers, according to PitchBook.